The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested identity is verified: ENSA encodes human alpha-endosulfine (also called ARPP-19e), corresponding to UniProt O43768. Human platelet proteomics explicitly identifies ENSA as O43768 and distinguishes it from the separate paralog ARPP19 (UniProt P56211). Both belong to the endosulfine family, but they are not interchangeable gene products and increasingly appear to have partly different cellular roles. No conflicting human gene identity was found. (thapa2022interactionmechanismof pages 1-3, kumm2020thecellcycle pages 7-9)
ENSA is not an enzyme, transporter, or structural protein. It is a small, predominantly intrinsically disordered regulatory phosphoprotein whose best-established primary function is to act, after phosphorylation, as a high-affinity inhibitor and slowly processed substrate of protein phosphatase 2A complexes containing a B55 regulatory subunit (PP2A-B55). Human MASTL/Greatwall phosphorylates ENSA at Ser67, converting it into the inhibitory form. This phosphoswitch allows phosphorylation established by CDK and other kinases to persist. A second site, Ser109, is phosphorylated by PKA and PKG and provides cAMP/cGMP-dependent regulation rather than strong PP2A inhibition by itself. (kumm2020thecellcycle pages 12-14, amin2022pp2ab55substratesand pages 9-11, kumm2019analysisofthe pages 114-116, kumm2019analysisofthe pages 16-19)
The most defensible location of action is inside the cell, principally in the soluble cytoplasmic/nucleocytoplasmic compartment, where ENSA encounters MASTL and PP2A holoenzymes. Precise cell-cycle-dependent localization of endogenous human ENSA remains poorly resolved. Historical KATP-channel experiments and recent mouse brain studies suggest extracellular or membrane-proximal effects, but neither a conventional secretion pathway nor direct physical channel binding has been established. (kumm2020thecellcycle pages 9-12, yee2004ratmesangialαendosulfine pages 6-7)
| Claim area | Best-supported conclusion | Evidence type/species | Confidence | Key caveat |
|---|---|---|---|---|
| Identity and paralog distinction | ENSA is human alpha-endosulfine/ARPP-19e, UniProt O43768; ARPP19 is a closely related but separate gene product, UniProt P56211. | Direct human proteomic identification plus comparative sequence/structural evidence (thapa2022interactionmechanismof pages 1-3, kumm2020thecellcycle pages 7-9) | High | Studies and antibodies frequently combine ENSA with ARPP19, so paralog-specific effects require careful verification. |
| Endosulfine family/domain and structure | ENSA belongs to the endosulfine family and is predominantly intrinsically disordered, with three transient alpha-helical regions rather than a stable catalytic fold. | Recombinant human ENSA studied by NMR, SAXS, and interaction assays (thapa2022interactionmechanismof pages 1-3) | High | The annotated Endosulfine domain denotes family membership; it is not an enzymatic catalytic domain. |
| Ser67 phosphorylation and PP2A-B55 inhibition | Human MASTL directly phosphorylates ENSA Ser67; phosphorylated ENSA functions as a potent inhibitor/substrate-trap of PP2A-B55, thereby opposing dephosphorylation of phosphoproteins. | Direct recombinant-human phosphorylation; PP2A-B55 potency and detailed specificity partly from Xenopus and conserved-system evidence (kumm2020thecellcycle pages 12-14, kumm2019analysisofthe pages 114-116, kumm2019analysisofthe pages 16-19) | High for phosphorylation; moderate-high for human holoenzyme specificity | The often-cited approximately 0.47 nM IC50 was derived from Xenopus-system work, not a definitive human-cell ENSA measurement. |
| Ser109 PKA/PKG regulation | PKA and PKG directly phosphorylate human ENSA Ser109; in platelets, cAMP- and cGMP-elevating agents increased this phosphorylation 4.81-fold and 3.75-fold, respectively. | Direct recombinant-human assays and quantitative human platelet phosphoproteomics (kumm2020thecellcycle pages 7-9, kumm2020thecellcycle pages 9-12) | High | Ser109 phosphorylation is regulatory but, unlike Ser67 phosphorylation, has not itself been shown to confer strong PP2A inhibition. |
| Intracellular localization | Available evidence supports ENSA as a soluble intracellular protein; orthologous rat mesangial ENSA was localized mainly to cytosol, with some particulate-fraction association. | Rat-cell immunofluorescence/fractionation; human intracellular detection in platelets and HEK293 cells (kumm2020thecellcycle pages 9-12, yee2004ratmesangialαendosulfine pages 6-7) | Moderate | Precise, dynamic localization of endogenous human ENSA across the cell cycle is insufficiently resolved; extracellular actions do not establish conventional secretion. |
| S-phase role | Mammalian genetic studies support an ENSA-biased function in S-phase/DNA-replication control, whereas ARPP19 is more critical for mitosis in mouse embryonic fibroblasts. | Mouse knockout/depletion studies summarized in an authoritative review (amin2022pp2ab55substratesand pages 9-11) | Moderate-high for mammals; moderate for humans | This division of labor is cell-type dependent and should not be interpreted as excluding a mitotic role for ENSA. |
| Platelet pathway | Human platelets contain ENSA and ARPP19 despite being anucleate; ENSA is more abundant at approximately 7,800 molecules per platelet versus approximately 2,500 ARPP19 molecules, and its Ser67/Ser109 sites are dynamically regulated. | Direct human platelet proteomics, phosphoproteomics, and biochemical assays (kumm2020thecellcycle pages 7-9, kumm2020thecellcycle pages 9-12, kumm2020thecellcycle pages 1-3) | High for presence and phosphorylation | The kinase responsible for endogenous Ser67 phosphorylation in platelets was not definitively identified because MASTL/MAST3 was not detected. |
| KATP channels and insulin secretion | Recombinant human alpha-endosulfine was reported to suppress sulfonylurea-sensitive KATP currents and stimulate insulin secretion, supporting a possible channel-modulatory role. | Human protein tested in heterologous/channel and insulin-secretion assays; additional rat-cell evidence (thapa2022interactionmechanismof pages 1-3, yee2004ratmesangialαendosulfine pages 6-7) | Moderate-low | The work predates the PP2A mechanism, required relatively high extracellular concentrations, and did not establish a physiological receptor, secretion route, or direct channel-binding mechanism. |
| SST–KATP–neprilysin–Aβ pathway | In mouse neurons and Alzheimer-model mice, ENSA was identified downstream of somatostatin signaling as a negative regulator of neprilysin; Ensa deficiency or KATP-channel modulation enhanced Aβ catabolism and reduced deposition. | Mouse primary neurons, knockout animals, proteomics, and pharmacology (watamura2022somatostatinevokedaβcatabolism pages 5-7, watamura2020αendosulfineregulatesamyloid pages 19-23) | Moderate-high for mouse models; low-moderate for humans | This is not direct evidence that human ENSA controls Alzheimer disease, and the relationship to ENSA's PP2A-B55 function remains unresolved. |
| Translational status | ENSA is a mechanistically credible research target in PP2A-B55 signaling and the preclinical KATP–neprilysin pathway, but no validated ENSA-directed drug, diagnostic test, or approved clinical implementation is established. | Structural human work plus preclinical mouse and pathway studies (thapa2022interactionmechanismof pages 1-3, watamura2022somatostatinevokedaβcatabolism pages 5-7) | High | Most therapeutic proposals target upstream MASTL, downstream PP2A/KATP signaling, or pathway effects rather than ENSA itself. |
Table: This table separates direct human ENSA evidence from mouse, rat, and Xenopus inference while rating confidence in each functional annotation. It highlights the well-supported PP2A-B55 phosphoswitch and the greater uncertainty surrounding localization, KATP-channel biology, and translation.
The target matches the supplied annotation in all essential respects:
The principal ambiguity is not the gene symbol but paralog attribution. ENSA and ARPP19 are closely related proteins with corresponding regulatory sites—ENSA Ser67/Ser109 and ARPP19 Ser62/Ser104—and many antibodies or experimental designs detect or manipulate both. Claims described as “ENSA/ARPP19” therefore cannot automatically be assigned to ENSA alone. Direct platelet measurements distinguish O43768 ENSA from P56211 ARPP19. (kumm2020thecellcycle pages 7-9, kumm2020thecellcycle pages 9-12)
Biophysical analysis of recombinant human ENSA by NMR and small-angle X-ray scattering found a predominantly intrinsically disordered protein containing three transient α-helical regions. Thus, the annotated endosulfine domain denotes a conserved regulatory family rather than a folded catalytic domain. Interaction assays indicated stronger association with the PP2A scaffold A subunit than with the tested B56 regulatory subunits, consistent with a multivalent “dock-and-coalesce” interaction. These B56/A-subunit observations broaden the physical interaction picture but do not overturn PP2A-B55 as the best-established functional phosphatase target. (thapa2022interactionmechanismof pages 1-3)
The core reaction is a regulatory phosphorylation, not a reaction catalyzed by ENSA:
MASTL + ENSA → MASTL + ENSA-pSer67
Phosphorylated ENSA then binds PP2A-B55 as a high-affinity inhibitory substrate. Its phosphoserine occupies the phosphatase catalytic machinery, but dephosphorylation is unusually slow relative to ordinary substrates. Consequently, a comparatively small inhibitory pool can block access of many conventional PP2A-B55 substrates. This is often called an “unfair substrate” or substrate-trap mechanism. When MASTL activity falls and pSer67-ENSA is eventually dephosphorylated, PP2A-B55 becomes available to reverse kinase-driven phosphorylation. The conserved acidic DSG region around the MASTL site and a C-terminal interaction cassette contribute to recognition. (amin2022pp2ab55substratesand pages 9-11, kumm2019analysisofthe pages 16-19)
Recombinant human MASTL directly and strongly phosphorylates human ENSA at Ser67. In conserved Xenopus biochemical systems, pSer67-ENSA inhibits PP2A-B55 with a reported IC50 of approximately 0.47 nM; dual Ser67/Ser109 phosphorylation gave approximately 0.52 nM. These values demonstrate exceptional potency, but they should not be presented as direct measurements in intact human cells. (kumm2020thecellcycle pages 12-14, kumm2019analysisofthe pages 16-19)
Functionally, the module can be summarized as:
CDK1 activation → MASTL activation → ENSA Ser67 phosphorylation → PP2A-B55 inhibition → preservation of kinase-dependent phosphorylation.
At pathway shutdown, loss of MASTL signaling and gradual ENSA dephosphorylation reactivate PP2A-B55, enabling ordered substrate dephosphorylation. This circuit is central to mitotic and meiotic phosphoregulation at the family level. However, mammalian genetics indicates that ARPP19 is frequently the dominant mitotic paralog, whereas ENSA has a stronger demonstrated contribution during S phase. (amin2022pp2ab55substratesand pages 9-11, matthews2014αendosulfine(ensa)regulates pages 2-4)
Purified PKA and PKG directly phosphorylate human ENSA at Ser109; mutation of Ser109 abolishes the corresponding recombinant-protein signal. In human platelets, iloprost-mediated cAMP signaling increased ENSA-pSer109 4.81-fold, while the soluble-guanylate-cyclase stimulator riociguat increased it 3.75-fold. The corresponding ARPP19-pSer104 increases were 3.53- and 2.18-fold. (kumm2020thecellcycle pages 7-9, kumm2020thecellcycle pages 9-12)
Ser109 phosphorylation should not be equated with the Ser67 inhibitory switch. Available experiments support strong PP2A inhibition by the MASTL-site phosphoprotein, whereas the C-terminal PKA/PKG site is regulatory and may alter recognition or dephosphorylation of the MASTL site. The two kinase systems can modify their respective sites with little direct interference in vitro. (kumm2020thecellcycle pages 12-14, amin2022pp2ab55substratesand pages 9-11, kumm2019analysisofthe pages 114-116)
Although ENSA and ARPP19 can both become PP2A-B55 inhibitors biochemically, mammalian loss-of-function studies argue for partial specialization. ENSA is particularly important for S-phase/DNA-replication control, whereas ARPP19 is more important for the temporal dephosphorylation program of mitosis in mouse embryonic fibroblasts. Arpp19 loss is embryonically lethal before gastrulation; Ensa loss has a different developmental course, and ENSA depletion perturbs S phase even where ARPP19 depletion does not. This is the strongest reason not to annotate ENSA simply as a generic mitotic factor. (amin2022pp2ab55substratesand pages 9-11)
A mitotic or meiotic role is nevertheless biologically plausible and experimentally supported in particular contexts. In mouse oocytes, ENSA-directed RNA interference reduced Ensa mRNA by 67 ± 11% and protein by 80 ± 6%, without changing Arpp19 mRNA, and impaired exit from prophase-I arrest. This provides paralog-resolved mammalian evidence that ENSA can participate in M-phase control. (matthews2014αendosulfine(ensa)regulates pages 2-4)
ENSA operates outside proliferating cells. Anucleate human platelets contain approximately 7,800 ENSA molecules per platelet, compared with approximately 2,500 ARPP19 molecules. Both Ser67 and Ser109 are dynamically phosphorylated, establishing that the module can regulate signaling rather than only nuclear division. (kumm2020thecellcycle pages 7-9, kumm2020thecellcycle pages 9-12)
Okadaic-acid inhibition of PP2A-like activity increased endogenous Ser67/Ser62-site phosphorylation and revealed a platelet kinase capable of phosphorylating recombinant ENSA. However, neither MASTL nor MAST3 was detected in the surveyed platelet proteomic/transcriptomic datasets, so assignment of endogenous platelet Ser67 phosphorylation specifically to MASTL remains unresolved. Pharmacological PP2A inhibition also changed platelet aggregation and phosphorylation of VASP, Akt, p38, and ERK1/2, but those effects reflect broad PP2A perturbation and are not all demonstrated as direct ENSA outputs. (kumm2020thecellcycle pages 12-14, kumm2020thecellcycle pages 1-3, kumm2020thecellcycle pages 9-12)
The original characterization of human alpha-endosulfine reported inhibition of sulfonylurea-sensitive KATP currents and stimulation of insulin secretion, leading to the hypothesis that ENSA is an endogenous sulfonylurea-like regulator. Subsequent rat mesangial and insulinoma work was directionally consistent with channel modulation. (thapa2022interactionmechanismof pages 1-3, yee2004ratmesangialαendosulfine pages 6-7)
This annotation should be regarded as provisional rather than primary. Effective extracellular concentrations were relatively high; a physiological secretion route, direct ENSA–channel binding interface, and relevant channel subunit specificity were not firmly established. The modern, mechanistically stronger annotation is phosphorylation-dependent PP2A-B55 inhibition. KATP-channel regulation may be a context-specific additional activity or an indirect pathway effect. (yee2004ratmesangialαendosulfine pages 6-7)
Mouse studies place ENSA downstream of somatostatin receptor signaling as a negative regulator of neprilysin, a protease that degrades amyloid-β. Somatostatin or an SSTR1/SSTR4 agonist increased neuronal neprilysin activity; conditioned-medium transfer and proteomics identified ENSA among candidate downstream factors. ENSA was also reported to be a neprilysin substrate, suggesting feedback between ENSA abundance and neprilysin activity. (watamura2022somatostatinevokedaβcatabolism pages 5-7)
In Ensa-deficient and Alzheimer-model mice, increased neprilysin activity was associated with reduced amyloid deposition, while pharmacological opening of a relevant KATP-channel subtype reduced amyloid burden and improved memory-related phenotypes. This is meaningful preclinical evidence for an SST–ENSA–KATP–neprilysin–Aβ axis, but it is mouse evidence and does not yet establish ENSA as a causal human Alzheimer-disease gene or validated therapeutic target. Its mechanistic relationship to ENSA’s PP2A-B55 activity also remains unresolved. (watamura2022somatostatinevokedaβcatabolism pages 5-7, watamura2020αendosulfineregulatesamyloid pages 19-23)
ENSA is best annotated as an intracellular soluble regulatory protein. Human ENSA is readily detected in platelet and HEK293 lysates as an approximately 17-kDa species. Rat mesangial-cell microscopy localized the ortholog mainly to the cytosol, with biochemical evidence for some particulate-fraction association. The disordered, soluble structure is consistent with dynamic interactions rather than residence in a membrane or stable organelle. (kumm2020thecellcycle pages 9-12, yee2004ratmesangialαendosulfine pages 6-7)
There is presently insufficient evidence to assign endogenous human ENSA to a single organelle or to claim constitutive secretion. Reports that conditioned medium or extracellular recombinant ENSA affects KATP-linked pathways indicate extracellular accessibility under experimental conditions, not a demonstrated classical secretory itinerary. Cell-cycle-dependent redistribution between cytoplasm and nucleus remains a reasonable possibility but is not adequately resolved by the evidence reviewed here.
The important recent developments mostly concern the broader MASTL–ENSA/ARPP19–PP2A-B55 module, not new ENSA-specific biochemistry:
Metabolic signaling (2023). Work on the MASTL/PP2A-B55 module showed that it supports mTORC1/S6K1-dependent negative feedback to IRS1 and GRB10 and thereby restrains PI3K–AKT activity. Phosphomimetic ENSA/ARPP19 constructs could rescue aspects of MASTL depletion, but because the experiments treated the paralogs together, this is pathway-level rather than ENSA-specific evidence. Publication: EMBO Journal, 2023; DOI: https://doi.org/10.15252/embj.2022110833.
Mammalian paralog dissection (2023). Mouse fibroblast work reported that ARPP19 was expressed more strongly and was the principal mitotic MASTL substrate, while ENSA silencing did not reproduce ARPP19’s proliferation phenotype. This reinforces the conclusion that ENSA should not be assigned all ARPP19 mitotic functions. Publication: March 2023; DOI: https://doi.org/10.1515/tjb-2022-0191. This interpretation agrees with earlier mammalian genetics showing an ENSA-biased S-phase role. (amin2022pp2ab55substratesand pages 9-11)
PP2A-B55 recognition (2024). High-resolution mutational scanning, structural modeling, and designed competitive peptides clarified how PP2A-B55 recognizes α-helical recruitment elements in substrates. This advances understanding of the phosphatase ENSA regulates, but it does not replace direct structural determination of a human ENSA–PP2A-B55 inhibitory complex. Publication: October 2024; DOI: https://doi.org/10.1126/sciadv.adp5491.
Cancer targeting (2024). Proteomic studies nominated upstream MASTL, rather than ENSA itself, as a potential gastric-cancer target; MASTL knockdown reduced proliferation, migration, and invasion in cell models. Publication: August 2024; DOI: https://doi.org/10.1186/s12964-024-01783-8. Such results support therapeutic interest in the axis but cannot be interpreted as proof that direct ENSA inhibition would be safe or effective.
The scarcity of ENSA-specific 2023–2024 mechanistic papers is itself informative: contemporary work frequently combines “ENSA/ARPP19,” studies upstream MASTL, or investigates downstream PP2A-B55. Functional annotation should therefore retain older, precise ENSA experiments rather than substitute newer but paralog-ambiguous studies.
There is no established ENSA-directed drug, approved diagnostic test, or clinical implementation. Current applications are research-oriented:
Cancer associations should be interpreted carefully. PP2A-B55 often has tumor-suppressive outputs, and excessive MASTL–endosulfine signaling can sustain phosphorylation programs favorable to tumors. Yet direct pharmacological ENSA blockade could affect DNA replication, cell-cycle fidelity, platelet signaling, and tissue-specific pathways. Current therapeutic development consequently focuses more heavily on MASTL or PP2A modulation than on ENSA. The structural demonstration that ENSA is disordered and uses distributed interaction surfaces also makes conventional small-molecule targeting challenging. (thapa2022interactionmechanismof pages 1-3, amin2022pp2ab55substratesand pages 9-11)
A conservative evidence-weighted annotation is:
Human ENSA is an intrinsically disordered endosulfine-family phosphoprotein that, when phosphorylated at Ser67 by MASTL/Greatwall-family kinase activity, inhibits PP2A-B55 and thereby preserves kinase-dependent phosphorylation. In mammalian cells it has a particularly supported role in S-phase/replication control, with context-dependent contributions to mitotic, meiotic, and non-dividing-cell signaling. PKA/PKG phosphorylation at Ser109 provides additional cyclic-nucleotide regulation. ENSA acts primarily intracellularly in the soluble cytoplasmic/nucleocytoplasmic compartment. Proposed KATP-channel and neprilysin-linked functions are biologically interesting but less established in humans.
The largest unresolved questions are the structure and kinetics of the complete human pSer67-ENSA–PP2A-B55 complex; precise endogenous localization through S phase; the degree of redundancy with ARPP19 in different human tissues; whether KATP effects require direct binding; and whether the mouse ENSA–neprilysin pathway translates to human brain biology.
References
(thapa2022interactionmechanismof pages 1-3): Chandan Thapa, Pekka Roivas, Tatu Haataja, Perttu Permi, and Ulla Pentikäinen. Interaction mechanism of endogenous pp2a inhibitor protein ensa with pp2a. The FEBS Journal, 289:519-534, Aug 2022. URL: https://doi.org/10.1111/febs.16150, doi:10.1111/febs.16150. This article has 10 citations.
(kumm2020thecellcycle pages 7-9): Elena J. Kumm, Oliver Pagel, Stepan Gambaryan, Ulrich Walter, René P. Zahedi, Albert Smolenski, and Kerstin Jurk. The cell cycle checkpoint system mast(l)-ensa/arpp19-pp2a is targeted by camp/pka and cgmp/pkg in anucleate human platelets. Cells, 9:472, Feb 2020. URL: https://doi.org/10.3390/cells9020472, doi:10.3390/cells9020472. This article has 33 citations.
(kumm2020thecellcycle pages 12-14): Elena J. Kumm, Oliver Pagel, Stepan Gambaryan, Ulrich Walter, René P. Zahedi, Albert Smolenski, and Kerstin Jurk. The cell cycle checkpoint system mast(l)-ensa/arpp19-pp2a is targeted by camp/pka and cgmp/pkg in anucleate human platelets. Cells, 9:472, Feb 2020. URL: https://doi.org/10.3390/cells9020472, doi:10.3390/cells9020472. This article has 33 citations.
(amin2022pp2ab55substratesand pages 9-11): Priya Amin, Sushil Awal, Suzanne Vigneron, Sylvain Roque, Francisca Mechali, Jean Claude Labbé, Thierry Lorca, and Anna Castro. Pp2a-b55: substrates and regulators in the control of cellular functions. Oncogene, 41:1-14, Oct 2022. URL: https://doi.org/10.1038/s41388-021-02068-x, doi:10.1038/s41388-021-02068-x. This article has 53 citations and is from a domain leading peer-reviewed journal.
(kumm2019analysisofthe pages 114-116): Elena Johanna Kumm. Analysis of the cell cycle regulatory system mastl-ensa/arpp19-pp2a in human platelets. Text, Jan 2019. URL: https://doi.org/10.25358/openscience-3038, doi:10.25358/openscience-3038. This article has 0 citations and is from a peer-reviewed journal.
(kumm2019analysisofthe pages 16-19): Elena Johanna Kumm. Analysis of the cell cycle regulatory system mastl-ensa/arpp19-pp2a in human platelets. Text, Jan 2019. URL: https://doi.org/10.25358/openscience-3038, doi:10.25358/openscience-3038. This article has 0 citations and is from a peer-reviewed journal.
(kumm2020thecellcycle pages 9-12): Elena J. Kumm, Oliver Pagel, Stepan Gambaryan, Ulrich Walter, René P. Zahedi, Albert Smolenski, and Kerstin Jurk. The cell cycle checkpoint system mast(l)-ensa/arpp19-pp2a is targeted by camp/pka and cgmp/pkg in anucleate human platelets. Cells, 9:472, Feb 2020. URL: https://doi.org/10.3390/cells9020472, doi:10.3390/cells9020472. This article has 33 citations.
(yee2004ratmesangialαendosulfine pages 6-7): Jerry Yee, Pedro Cortes, Jeffrey L. Barnes, Rebecca Alviani, Jason I. Biederman, and Balázs Szamosfalvi. Rat mesangial α-endosulfine. Kidney International, 65:1731-1739, May 2004. URL: https://doi.org/10.1111/j.1523-1755.2004.00578.x, doi:10.1111/j.1523-1755.2004.00578.x. This article has 11 citations and is from a highest quality peer-reviewed journal.
(kumm2020thecellcycle pages 1-3): Elena J. Kumm, Oliver Pagel, Stepan Gambaryan, Ulrich Walter, René P. Zahedi, Albert Smolenski, and Kerstin Jurk. The cell cycle checkpoint system mast(l)-ensa/arpp19-pp2a is targeted by camp/pka and cgmp/pkg in anucleate human platelets. Cells, 9:472, Feb 2020. URL: https://doi.org/10.3390/cells9020472, doi:10.3390/cells9020472. This article has 33 citations.
(watamura2022somatostatinevokedaβcatabolism pages 5-7): Naoto Watamura, Naomasa Kakiya, Per Nilsson, Satoshi Tsubuki, Naoko Kamano, Mika Takahashi, Shoko Hashimoto, Hiroki Sasaguri, Takashi Saito, and Takaomi C. Saido. Somatostatin-evoked aβ catabolism in the brain: mechanistic involvement of α-endosulfine-katp channel pathway. Molecular Psychiatry, 27:1816-1828, Nov 2022. URL: https://doi.org/10.1038/s41380-021-01368-8, doi:10.1038/s41380-021-01368-8. This article has 34 citations and is from a highest quality peer-reviewed journal.
(watamura2020αendosulfineregulatesamyloid pages 19-23): Naoto Watamura, Naomasa Kakiya, Per Nilsson, Satoshi Tsubuki, Naoko Kamano, Mika Takahashi, Shoko Hashimoto, Hiroki Sasaguri, Takashi Saito, and Takaomi C. Saido. Α-endosulfine regulates amyloid β 42 via the modulation of neprilysin activity. bioRxiv, Oct 2020. URL: https://doi.org/10.1101/2020.10.07.329318, doi:10.1101/2020.10.07.329318. This article has 2 citations.
(matthews2014αendosulfine(ensa)regulates pages 2-4): Lauren Matthews and Janice Evans. Α-endosulfine (ensa) regulates exit from prophase i arrest in mouse oocytes. Cell Cycle, 13:1639-1649, May 2014. URL: https://doi.org/10.4161/cc.28606, doi:10.4161/cc.28606. This article has 16 citations and is from a peer-reviewed journal.